StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultAug 13, 2026, 04:14 PM

Nuwellis Q2 Net Loss Narrows to $4.8M; Going Concern Doubt

AI Summary

Nuwellis, Inc. reported a narrowed net loss of $4.8 million for Q2 2026, down from $12.6 million in Q2 2025, with net sales increasing to $1.97 million. Despite improved financial performance, the company disclosed substantial doubt about its ability to continue as a going concern due to accumulated deficits and continued operating losses. Nuwellis raised $4.9 million in net proceeds from a June 2026 stock offering and $4.4 million from a January 2026 private placement to support operations.

Key Highlights

  • Q2 2026 net sales increased to $1.97 million from $1.73 million YoY.
  • Q2 2026 net loss narrowed to $(4.8) million from $(12.6) million YoY.
  • Basic & diluted loss per share improved to $(26.64) from $(2,134.19) YoY.
  • Accumulated deficit reached $(325.7) million as of June 30, 2026.
  • Net cash provided by financing activities was $9.42 million for YTD 2026.
  • Total liabilities increased to $11.17 million from $3.49 million since Dec 31, 2025.
  • Effectuated a 1-for-35 reverse stock split on June 25, 2026.
  • Acquired Rendiatech Ltd. on March 17, 2026.